Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

Add-on stiripentol useful for long-term treatment of refractory epilepsies

28 Nov 2019

Use of stiripentol as an adjunctive treatment in patients with different types of refractory epilepsies, including focal onset epilepsy without bilateral tonic‐clonic seizures, has demonstrated long-term efficacy in a prospective observational study.

Researchers followed 132 individuals (age, 5 months to 43 years) consecutively treated with stiripentol as an adjunctive therapy for refractory epilepsies for a median of 14.8 months. Of these patients, 30 had Dravet syndrome (DS),

Stiripentol was administered at a starting dose of 10–15 mg/kg/d, with weekly increments up to a maximum of 50 mg/kg/d based on both age and weight. Epilepsy aetiology was classified as structural, genetic, infectious, immune, metabolic and unknown.

In the cohort, 29 patients (22 percent) received more than two antiepileptic drugs. The most commonly used add-on drugs were benzodiazepines, mainly clobazam. Sixty-six patients (50 percent) achieved response, defined as a reduction in seizure frequency of ≥50 percent), and 13 of them (9.8 percent) were seizure‐free.

The rate of response was higher in the genetic aetiology group (57 percent), particularly in DS (18/30; 60 percent), and in the group of patients with refractory focal onset epilepsy without bilateral tonic‐clonic seizures (5/15; 33 percent).

Median relapse‐free survival rate was 27 months in the 66 responders. The median time to stiripentol failure was 24.6 months in the entire cohort.

More prospectively designed studies are required to confirm the efficacy of stiripentol in focal epilepsy, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.